Achilles Therapeutics PLC ADR (ACHL) Stock
ACHL is no longer traded. Achilles Therapeutics PLC ADR was delisted from the Nasdaq in March 2025.
Prices on this page are historical; the last trade was March 20, 2025 at $1.48.
Achilles Therapeutics PLC ADR stock price history
ACHL final trading statistics
- Final close
- $1.48
- Final trading day
- Mar 20, 2025
- Market cap at delisting
- $60.83M
- Shares outstanding
- 41.10M
- Final 52-week range
- $0.63 – $1.51
- Avg. volume (final 3 mo.)
- 1,272,406
- All-time high (split-adj.)
- $17.86 · Apr 2021
- All-time low (split-adj.)
- $0.70 · Sep 2024
- Return since IPO
- -91.1%
- Beta
- 1.25
- Book value / share
- $2.51
- Price / book
- 0.59
Achilles Therapeutics PLC ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$69.7M | -$1.74 |
| FY2022 | $0.00 | -$71.2M | -$1.82 |
| FY2021 | $0.00 | -$61.1M | -$9.62 |
| FY2020 | $0.00 | -$33.2M | -$4.70 |
| FY2019 | $0.00 | -$14.0M | -$5.71 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Achilles Therapeutics PLC ADR
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Achilles Therapeutics PLC ADR stock FAQ
What happened to Achilles Therapeutics PLC ADR stock?
Achilles Therapeutics PLC ADR stock was delisted from the Nasdaq. Its final close was $1.48 on March 20, 2025.
Is ACHL stock still trading?
No. ACHL was delisted from the Nasdaq in March 2025 and no longer trades on a U.S. exchange.
What was the last price of ACHL stock?
ACHL closed at $1.48 on its final trading day, March 20, 2025, for a market value of about $60.83M.
What were Achilles Therapeutics PLC ADR's revenue and earnings in its last full fiscal year?
Achilles Therapeutics PLC ADR reported revenue of $0.00 and net income of -$69.7M in fiscal 2023, its last full year as a public company.
When did Achilles Therapeutics PLC ADR go public?
Achilles Therapeutics PLC ADR stock began trading on March 31, 2021.